We pursue systematic reviews and/or meta-analyses to answer a research question. If a review already answers your question, this existing review can be the foundation of your next research project!
Sometimes it is still important to pursue a review, even if your original research question(s) have been answered. What is considered "the same" review is not always clear. Generally speaking, you need to justify that and illustrate how your new review contributes something unique to the field.
If a review already answers your question, and your team would still like to pursue a review, your team can:
According to Garner, et al., (2016) , "The decision [of whether or not to update] needs to take into account whether the review addresses a current question , uses valid methods , and is well conducted ; and whether there are new relevant methods , new studies , or new information on existing included studies. Given this information, the agency, editors, or authors need to judge whether the update will influence the review findings or credibility sufficiently to justify the effort in updating it."
Bashir, R., et al. Time-to-update of systematic reviews relative to the availability of new evidence. Syst Rev 7, 195 (2018). https://doi.org/10.1186/s13643-018-0856-9
Garner, P., et al. Panel for updating guidance for systematic reviews (PUGs). (2016). When and how to update systematic reviews: Consensus and checklist . BMJ , i3507. https://doi.org/10.1136/bmj.i3507
Review replication is not often pursued due to the amount of time and labor required. However, Pieper, Heß, & Faggion (2021) have developed a framework for replicating, and the replication process is a great learning tool.
You may find other reviews (e.g., scoping review, restricted (or rapid) review) on your topic exist - that's great, as these might provide further insight to the appropriateness of the systematic review method for your research question(s) and how to frame your own review approach .
What is 'seminal work'.
In general, seminal work also called pivotal , landmark , or seed studies, are articles that are central to the research topic and have great importance and influence within the discipline. Seminal articles are likely to be cited frequently in different journal articles, books, dissertations etc.
In systematic reviews and/or meta-analyses, seminal work are the "seed articles" for your specific review - the articles (or other material) you know need to be included in your final synthesis. These articles may have sparked the teams interest in pursuing a review or may be identified through the exploratory search.
Seminal articles can be helpful when identifying where to search and developing the search strategy !
In short, where you exploratory search will depend on your research question. In other words, you should consider searching wherever you are likely to find material that answers your research question.
In addition to repositories, you'll want to search academic journal databases that may be relevant to your topic. Consider your topic from perspectives other than your own discipline - it's likely your topic overlaps with several disciplines. For example, if you are examining a public health topic, it may be useful to search databases related to health / medicine and social sciences.
You can also use this exploratory phase to determine whether a database is relevant and should be searched as part of your final comprehensive systematic review search strategy, or not.
Hint: Sort "By Subject" to find relevant guides
Web browsing in Google or Google Scholar is a great place to start finding seminal works and existing reviews, as well as journals and databases in which you should conduct more robust exploratory searches.
Never rely only on web browsing . While Google Scholar (and Google) are great places to start searching, results are tailored to individual users, are not replicable, and algorithms are not transparent. More guidance for web browsing is located in the "Where to Search" sub-tab of the "Comprehensive Search" section of this guide.
The possibilities of where to exploratory search are endless! Consider searching anywhere that seminal articles or existing/in-progress reviews relevant to your scope may exist. Here are a few more places to get you started.
Researchers use these sites to share unpublished or in-progress research and reviews, procedural documentation, and other grey literature. For example:
Researchers uses these sites to openly share research , some of which is not yet published (or peer-reviewed), also called 'preprints'. For example:
There are several systematic review repositories that exist - some contain only published reviews , while others include review registrations and protocols . In the following table, we present and link out to some repositories that specifically house systematic reviews and similar evidence synthesis publications .
Campbell Collaboration Registry
"...all registered titles for systematic reviews or evidence and gap maps that have been accepted by the Editor of a Campbell Coordinating Group. When titles progress to protocol stage, the protocol is published in the Campbell Systematic Reviews journal."
Campbell Systematic Review Journal
Both registry and journal include topics related to Business and Management, Climate Solutions, Crime and Justice, Disability, Education, International Development, Knowledge Translation and Implementation, and Social Welfare
Cochrane Database of Systematic Reviews (CDSR)
"...the leading journal and database for systematic reviews in health care. CDSR includes Cochrane Reviews (systematic reviews) and protocols for Cochrane Reviews as well as editorials and supplements."
Cochrane Library
"Cochrane Collaboration produces high-quality systematic reviews in health disciplines. For more detail and specific fields of research, check out the Cochrane Review Groups and Networks. "
Database of promoting health effectiveness reviews (DoPHER)
"...focussed coverage of systematic and non-systematic reviews of effectiveness in health promotion and public health worldwide. This register currently contains details of over 6,000 reviews of health promotion and public health effectiveness."
Epistemonkios
"...a collaborative, multilingual database of health evidence. It is the largest source of systematic reviews relevant for health-decision making, and a large source of other types of scientific evidence."
Health Evidence
"...quality-rated systematic reviews evaluating the effectiveness and cost-effectiveness of public health interventions, including cost data."
Joanna Briggs Systematic Review
"...a collection of world-class resources driven by the needs of health professionals and consumers worldwide"
"International database of prospectively registered systematic reviews in health and social care, welfare, public health, education, crime, justice, and international development, where there is a health related outcome."
Discover the world's research
To read the full-text of this research, you can request a copy directly from the authors.
Debunking palliative care myths: assessing the performance of artificial intelligence chatbots (chatgpt vs. google gemini), perceptions and attitudes of nurse practitioners toward artificial intelligence adoption in health care, managing healthcare innovation activities in kazakhstan for optimal effectiveness, championing health systems management with digital innovation and applications in the age of artificial intelligence: protocol for a research program, determinants of artificial intelligence-assisted diagnostic system adoption intention: a behavioral reasoning theory perspective, the use of generative ai for scientific literature searches for systematic reviews: chatgpt and microsoft bing ai performance evaluation, analyzing the impact of ai on knowledge acquisition of students, hospital innovations for the next decade, fintech frenzy: an engaging review of the transforming financial services, investigating the influence of stakeholders' collaboration on open innovation in healthcare, 110 references, artificial intelligence (ai)-enabled crm capability in healthcare: the impact on service innovation, chatbots for future docs: exploring medical students’ attitudes and knowledge towards artificial intelligence and medical chatbots, machine learning to improve frequent emergency department use prediction: a retrospective cohort study, the potential impact of artificial intelligence on healthcare spending, developing robust benchmarks for driving forward ai innovation in healthcare, understanding the acceptance of emotional artificial intelligence in japanese healthcare system: a cross-sectional survey of clinic visitors’ attitude, changes in radiology due to artificial intelligence that can attract medical students to the specialty, using machine learning to predict hospital disposition with geriatric emergency department innovation intervention., acceptance of clinical artificial intelligence among physicians and medical students: a systematic review with cross-sectional survey, integrating artificial intelligence into haematology training and practice: opportunities, threats and proposed solutions, related papers.
Showing 1 through 3 of 0 Related Papers
Question Does adenotonsillectomy increase the risk of undesirable weight gain in children with mild obstructive sleep-disordered breathing?
Findings This exploratory analysis of data from the Pediatric Adenotonsillectomy Trial for Snoring (PATS) randomized clinical trial included 375 children with mild obstructive sleep-disordered breathing and did not demonstrate an increased risk of undesirable weight gain during the first 12 months after adenotonsillectomy vs observation.
Meaning These findings indicate that clinicians can reassure parents that adenotonsillectomy alone is unlikely to result in undesirable weight gain in children.
Importance It is unknown whether adenotonsillectomy causes undesirable weight gain in children with mild obstructive sleep-disordered breathing (oSDB).
Objective To compare changes in anthropometric measures in children with mild oSDB treated with adenotonsillectomy vs watchful waiting.
Design, Setting, and Participants This was an exploratory analysis of the Pediatric Adenotonsillectomy Trial for Snoring (PATS) randomized clinical trial of adenotonsillectomy vs watchful waiting for mild oSDB (snoring with obstructive apnea-hypopnea index of <3 events/hour) that took place at 7 pediatric tertiary care centers across the US and included 458 children aged 3.0 to 12.9 years with mild oSDB. Participants were recruited from June 29, 2016, to February 1, 2021. Anthropomorphic measures taken at baseline and 12 months after randomization were standardized for age and sex, including each participant’s percentage of the 95th body mass index percentile (%BMIp95). Data analyses were performed from March 15, 2023, to April 1, 2024.
Intervention Early adenotonsillectomy (eAT) vs watchful waiting with supportive care (WWSC).
Main Outcomes and Measures Twelve-month change in %BMIp95 from baseline and undesirable weight gain (defined as any weight gain in a child who already had overweight or obesity or an increase from baseline normal weight/underweight to overweight/obesity) at follow-up assessment.
Results The study analysis included 375 children (mean [SD] age, 6.1 [2.3] years; 188 [50.2%] females), of whom 143 (38%) had overweight or obesity at baseline. At 12 months, children in the eAT group experienced a 1.25-point increase in %BMIp95 compared with a 0.59-point increase in the WWSC group (mean difference, 0.93; 95% CI, −0.39 to 2.25). Undesirable weight gain was also similar between the eAT (n = 120; 32%) and WWSC (n = 101; 27%) groups (mean difference, 4%; 95% CI, 5% to 14%).
Conclusions and Relevance The findings of this exploratory analysis of the PATS trial indicate that adenotonsillectomy was not independently associated with an increased risk of undesirable weight gain in children with mild oSDB. However, one-third of the children gained undesirable weight during the study, which suggests that there is an opportunity to address healthy weight management during the evaluation and treatment of children with mild oSDB.
Trial Registration ClinicalTrials.gov Identifier: NCT02562040
Kirkham EM , Ishman S , Baldassari CM, et al. Weight Gain After Adenotonsillectomy in Children With Mild Obstructive Sleep-Disordered Breathing : Exploratory Analysis of the PATS Randomized Clinical Trial . JAMA Otolaryngol Head Neck Surg. Published online August 22, 2024. doi:10.1001/jamaoto.2024.2554
© 2024
Artificial Intelligence Resource Center
Otolaryngology in JAMA : Read the Latest
Browse and subscribe to JAMA Network podcasts!
Select your interests.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Seume, E, Göing, J, & Friedrichs, J. "A Literature Review on Data Sources and Methodologies for Enriching Gas Path Analysis With Earth Observation Data." Proceedings of the ASME Turbo Expo 2024: Turbomachinery Technical Conference and Exposition . Volume 1: Aircraft Engine . London, United Kingdom. June 24–28, 2024. V001T01A015. ASME. https://doi.org/10.1115/GT2024-122772
Download citation file:
Aero engine performance and condition deterioration are a function of operational severity. Operational severity is determined by various aspects such as airborne contaminants, derates, ambient temperature, humidity, and precipitation. More severe operating environments induce cost, which should be managed by using earth observation (EO) data in engine health monitoring. This paper presents an analytical approach that incorporates a broad set of EO data into engine health management and subsequent maintenance planning. Current approaches to gas path analysis are extended by incorporating EO data. The analytical approach is presented in combination with a literature review. The literature review covers the following topics: flight trajectory modeling, EO/environmental condition data, as well as engine performance, condition, and deterioration modeling. Methods and data sources in these different areas are reviewed while simultaneously presenting the currently researched analytical approach. The researched analytical approach creates high-resolution contamination profiles for a flight trajectory on a global scale. Weather conditions and the ingestion of aerosols and sand are monitored and correlated with aero engine condition and performance. A wide range of data sources are presented, which however only partly cater to the needs of the Maintenance, Repair and Overhaul community.
Product added to cart., email alerts, related proceedings papers, related articles, related chapters, affiliations.
Sign In or Create an Account
Literature review: emerging innovations and best practices in social research - key takeaways for humanitarian and development action (july 2024).
Introduction
Applied social research is a field of study which aims to understand and address real-world problems, through the application of research methods in sociology, psychology, anthropology and related fields, to gain insights into specific phenomena and inform decision-making in public policy and similar practical contexts. Over recent decades, the field has experienced transformative changes driven by technological advancements, globalization, and evolving methodologies. Moreover, social research has become essential in shaping humanitarian and development action, providing crucial insights that guide interventions, policies, and resource allocation, across different contexts of crisis.
As one of the largest independent research actors currently operating in crisis contexts, IMPACT Initiatives (IMPACT), with support from the USAID Bureau of Humanitarian Assistance (BHA), launched an in-depth literature review at the beginning of 2024 to understand what the emerging innovations and best practices in the field of social research are, and how these can be applied for research efforts within the humanitarian and development sector.
This paper summarises the key findings from this literature review, broken down into four chapters. In chapter 2, the most important evolutions from the last decades will be discussed, from digital transformation, Open Access, globalization, and the emergence of more interdisciplinary and participatory research approaches. In chapter 3, some common applications of social research for humanitarian and development contexts from recent years will be discussed, including key innovations in terms of new technologies, methods and tools. In chapter 4, the relationship between social research and policymaking will be analysed, exploring how research influences policy decisions and the key challenges and enablers in this process. Case studies to illustrate successful integrations of research into policymaking will also be discussed within this chapter. Finally, chapter 5 will be dedicated to the conclusions and recommendations, summarizing key takeaways, offering suggestions and highlighting remaining information gaps that need to be addressed for future research efforts, by IMPACT or similar organisations.
Data-driven digital agriculture, ai in emergency response: not the time for experiments.
World + 22 more
Bureau de la représentante spéciale du secrétaire général pour la question des enfants et des conflits armés (a/79/245).
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
Find support for a specific problem in the support section of our website.
Please let us know what you think of our products and services.
Visit our dedicated information section to learn more about MDPI.
Limited evidence for the benefits of exercise in older adults with hematological malignancies: a systematic review and meta-analysis.
1. introduction, 2. materials and methods, 2.1. information sources and search strategy, 2.2. eligibility criteria, 2.3. data collection process, 2.4. outcomes, 2.5. risk of bias assessment, 2.6. certainty of evidence, 2.7. data synthesis and analysis, 3.1. study characteristics, 3.2. exercise interventions, 3.3. effects of exercise interventions on primary outcomes, 3.4. effects of exercise interventions on secondary outcomes, 3.5. feasibility, adverse events, adherence and exclusion criteria, 3.6. risk of bias in individual studies and across studies, 3.7. quality of evidence (grade), 3.8. ongoing studies registered in clinical trials, 4. discussion, strengths and limitations, 5. conclusions, supplementary materials, author contributions, institutional review board statement, informed consent statement, acknowledgments, conflicts of interest.
Click here to enlarge figure
Author, Year, Country | Diagnose | Study Design | Sample Size, n IG/CG Female (%) | Age Mean, (Range) Median, (Range) | Exclusion Criteria | Timing of Intervention | Intervention Group | Control Group | |
---|---|---|---|---|---|---|---|---|---|
Type: T Intensity: I Length: L Duration: D | Extensiveness | Type: T Intensity: I Length: L Duration: D | |||||||
Accogli 2022 Italy [ ] | Lymph, Leuk, MM | RCT | 46 (23/23) (47.8) | Mean 59.9 Median IG: 66.7 (51.3–72.1) CG: 60.4 (49.9–67.5) | Poor prognosis (<12 months) and clinical conditions hindering participation (e.g., dementia, psychiatric pathology, blindness) | Before, during and after chemotherapy | Supervised, hospital-based: T: Therapeutic education I: Individual intensity L: 2 × 60 min (group) and face-to-face (individual) 6 × 20 min 1x/week or every 2 weeks Unsupervised, homebased: T: Individual physical exercise D: 8 weeks | Less | T: Educational therapeutic group sessions L: 2x in total |
Alibhai 2014 Canada [ ] | AML | RCT Feasibility | 38 (21/17) (55.3) | Mean 56.1 IG: 53.9 CG: 58.8 | Another active malignancy, life expectancy < 3 months, severe or unstable cardiorespiratory or musculoskeletal disease, awaiting HSCT and regular participation in a moderate-vigorous PA program | After HSCT or chemotherapy | Supervised, hospital-based: T: Workout and education (group) L: 1.5 h/week Unsupervised, home-based: T: Aerobic, resistance and flexibility components I: Moderate intensity L: 30 min, 3–5x/week D: 12 weeks | Moderate | T: UC, Usual level of PA |
Alibhai 2015 Canada [ ] | AML | RCT | 81 (57/24) (45.7) | Mean 57 (23–80) IG: 58 CG: 52 Median 59 >60: IG, n = 32 CG, n = 7 | Another active malignancy, life expectancy < 1-month, significant medical comorbidity that would preclude exercise, uncontrolled pain, hemo-dynamic instability | During chemotherapy | , hospital-based: T: Individualized aerobic (treadmill, hall walking, stationary cycling), resistance (body weight, bands, free weights) and flexibility training I: RPE of 3–6, equivalent to 50–75% of HRR L: 30–60 min, 4–5x/week | Moderate | T: UC, Suggestions to walk regularly and weekly document on tracking sheets |
Baumann 2010 Germany [ ] | AML, ALL, CML, MM, NHL/CLL, MDS/MPS, Solid tumor, Immuno-deficiency | RCT Pilot | 64 32/32 (45.4) | Mean IG: 44.9 CG: 44.1 | Severe orthopaedic illness of legs, severe heart failure (NYHA III-IV), metastatic bone disease, thrombocytopenia (≤30 × 10 /L) and/or acute somatic complaint (e.g., infection, fever, acute bleeding) | During ASCT, allo-HSCT or chemotherapy | hospital-based: T: Aerobic (ergometer) and ADL training (walking, stepping, stretching) I: Aerobic: 80% of achieved watt load in WHO-test, ADL-training: Borg scale: “slighty strenuous”-“strenuous” L: Aerobic 10–20 min + ADL 20 min/2x daily, ADL 5x/week D: Mean: 26.6 days | Moderate | T: UC, Standard mobilization program |
Baumann 2011 Germany [ ] | AML ALL, CML, CLL, MPS, MDS, CMML, MM, PID | RCT | 47 (24/23) (51.5) | Mean IG: 41.4 CG: 42.8 | Severe cardiac disease (NYHA III-IV) or orthopaedic illness of the legs, bone metastases, thrombocytopenia (≤10 × 10 /L) or acute bleeding, respectively, and/or acute health or somatic complaints (e.g., infection, fever) | During allo-HSCT | hospital-based: T: Aerobic (ergometer) and ADL training (walking, stepping, stretching) I: Aerobic: 80% of achieved watt load in WHO-test, ADL-training: Borg scale: “slighty strenuous”-”strenuous L: Aerobic: 10–20 min + ADL 20 min, 1–2x/day D: Mean: 56.1 days | Moderate | T: UC, Standard PT |
Bayram 2024 Turkey [ ] | ALL, AML, Biphenotypic Leuk, MDS, NHL, Burkitt Lymph, CNS Lymph, Myelofibrosis, Thalassemia major, MM | RCT | 30 (15/15) (26.7) | Mean IG: 45.67 CG: 52.07 | Orthopaedic, neurological, or cognitive disease affecting functional capacity, psychiatric disorders, pneumonia, acute infections, sepsis, and pulmonary diseases | During HSCT | hospital-based: T: Aerobic (arm ergometer), resistance (free weights) and inspiratory muscle (inspiratory pressure device) exercises I: Aerobic: 50–80% of HR. Resistance: 4–6 on modified Borg scale, 3 sets of 10 reps. Inspiratory: 30% of max inspiratory pressure L: Aerobic: 10–30 min, 1x/day, 5 days/week. Resistance: 10–15 min, 5 days/week. Inspiratory: 15 min, 2x/day, 5 days/week D: During inpatient period. Mean: 25.2 days | Extensive | T: Aerobic and resistance exercises I: As IG L: As IG D: During inpatient period. Mean: 21.33 days |
Bird 2010 UK [ ] | Leuk, Lymph, MM, other | RCT | 58 (29/29) (34.5) | Median 55 IG: 57 CG:52 | NR | After ASCT or allo-HSCT | hospital-based: T: Circuit training exercise, relaxation, and information (group) I: NR L: 1x/week D: 10 weeks | Less | T: UC, Self-managed program: information leaflets and home-based exercise program |
Bryant 2018 USA [ ] | AML, ALL | RCT Pilot | 18 (9/9) (29.4) | Mean IG: 52 (34–67) CG: 49 (28–69) Median IG: 58 (34–67) CG: 48 (28–69) | Cardiovasc. disease, acute or chronic respiratory disease, acute or chronic bone, muscle, or joint abnormalities, altered mental state, dementia or any other psychological condition, another active malignancy, active bleeding, acute thrombosis, ischemia, hemodynamic instability, or uncontrolled pain | During chemotherapy | hospital-based: T: Aerobic (walking or stationary bike) and resistance training (resistance band) I: Aerobic: 50–70% of HRR. Resistance: Increased from lighter to heavier resistance, 10 RM L: 20–40 min, 2x/day, 4x/week D: 4 weeks | Moderate | T: UC |
Chang 2008 Taiwan [ ] | AML | RCT | 24 (12/12) (45.5) | Mean IG: 49.4 CG: 53.3 | NR | During chemotherapy | hospital-based: T: Walking exercise program I: A speed to reach target HR (resting heart rate plus 30) L: 12 min, 5x/week D: 3 weeks | Less | T: Nurse-led control L/D: 1x/day, 5 days/week, 3 weeks |
Chen 2021 China [ ] | AML, ALL | RCT Pilot | 30 (15/15) (58.6) | Mean IG: 40.2 CG: 37.6 | Medical conditions in arms, legs, or abdomen, paralysis, or disability and intended to receive HSCT in the next 3 months | During chemotherapy | , hospital-based T: Individualized self-help relaxation exercises I: NR L: 30 min, 2x daily D: 4 weeks | Less | T: UC |
Chow 2020 USA [ ] | Leuk, Lymph, other | RCT Pilot | 41 (24/17) (48.8) | Median 45.1 (20.2–54.8) IG: 44.0 (20.9–54.0) CG: 46.0 (20.2–54.8) | Pre-existing ischemic heart disease or ongoing symptomatic cardiomyopathy, active cGvHD, pregnant | After ASCT, allo-HSCT | , home-based: T: Individualized, multiple mHealth app-based lifestyle counselling and goal-setting intervention, step count goals based on the past week’s daily average steps I: NR L: 16 weeks | Less | T: Fitbit tracker and Healthwatch360 app, no goal setting or peer support |
Chuang 2017 Taiwan [ ] | NHL | RCT | 100 (50/50) (45.0) | Mean IG: 55.9 CG: 64.5 | Major medical disease, MM, or bone metastasis with medical contra-indications for exercise and already practicing qigong or other exercise regular | During chemotherapy | , home-based: T: Chan-Chuang qigong program with weekly telephone calls I: NR L: 25 min, 2–3x/day D: 21 consecutive days | Less | T: UC, Nursing on side effects of chemotherapy and care |
Cohen 2004 USA [ ] | Lymph, HL, NHL | RCT | 39 (20/19) (30.8) | Mean 51 | Major psychotic illness, <18 years | During and after chemotherapy | , hospital-based: T: Group-based Tibetan yoga program I: NR L: 7x/week D: 7 weeks | Less | T: UC |
Coleman 2003 USA [ ] | MM | RCT Pilot Feasibility | 24 (14/10) (41.7) | Mean 55 (42–74) | NR | During chemotherapy and ASCT | , home-based: T: Aerobic (walking, running, or cycling) and strength training (exercise bands), exercise log I: Borg Scale 12–15 L: Approx. 50 min, individual frequency D: 26 weeks | Moderate | T: UC, Encouragement to remain active and walk |
Coleman 2012 USA [ ] | MM | RCT | 187 (95/92) (41.7) | Mean IG: 56.0 (25–76) CG: 56.4 (35–76) | Unable to understand intent of the study, major psychiatric illness, or presence of microcytic or macrocytic anaemia, uncontrolled hypertension, RBC transfusions within two weeks of study enrolment, or recombinant epoetin alfa within eight weeks of study enrolment | During unspecified intensive treatment (PBSCT) | , home-based: T: Individualized combination of stretching, aerobic exercise (walk, jog on treadmills) and strength resistance training (exercise bands), exercise log I: Aerobic:65–80% max HR, Borg Scale 11–13. Strength: 60–80% of 1 RM L: Individual length and frequency D: 15 weeks | Moderate | T: UC, Recommendation to walk L: 20 min, 3x/week |
Courneya 2009 Canada [ ] | Lymph, NHL indolent, NHL aggressive, HL | RCT | 122 (60/62) (41) | Mean 53.2 (18–80) >60: n = 49 | Uncontrolled hypertension, cardiac illness, resides >80 km from facility, not approved by oncologist | Before, during and after chemotherapy | , hospital-based: T: Aerobic (ergometer) I: Initial 60% of VO peak, progressing 75% L: 15–45 min, 3x/week D: 12 weeks | Moderate | T: UC, Supervised exercise L: 12 sessions, 1 month, after postintervention assessments |
Defor 2007 USA [ ] | AA, ALL, AML, MDS, CML, NHL/HL, other malignancies | RCT | 100 (51/49) (39.0) | Median 47 (18–68) IG: 46 (18–68) CG: 49 (22–64) | Unavailable treadmills at hospital admission (n = 21 excluded) | During and after allo-HSCT From transplant admission to day 100 posttransplant | Supervised, hospital-based: T: Individualized treadmill I: Comfortable speed L: 15 min, 2x/day , homebased: T: Walking I: Comfortable speed L: 30 min, 1x/day | Moderate | T: UC, Not asked to perform any formal exercise |
Eckert 2022 USA [ ] | BMT patients | RCT Feasibility | 72 (33/39) (55.6) | NR | Engaged in yoga in past year, history of recurrent falls (>two falls in 2 months), residency outside USA, participation in a previous study with the research team, ECOG 3 questionnaire score > 3, pregnant | After ASCT | , home-based: T: Online Hatha yoga program I: NR L: Min. 60 min/week D: 12 weeks | Less | T: Online cancer health education podcasts L: 60 min/week D: 12 weeks |
Furzer 2016 Australia [ ] | NHL, HL, MM | RCT | 37 (18/19) (NR) | Mean 48.9 (22–68) IG: 48.2 (22–64) CG: 49.6 (25–68) | Hematologist did not approve exercise due to identified risks | After chemotherapy or radiation or HSCT | , in local gyms and clinics: T: Aerobic (individual) and resistance training (machines and dumbbells) I: Cardio: 50–85% of HRmax, RPE of 10–16. Resistance: Initial 3 sets of 10–15 rep at 50% of 1 RM to 2–3 sets of 6–8 rep at 80% of 1 RM L: Max. 30 min, 3x/week D: 12 weeks | Moderate | T: Diary and general healthy lifestyle advice |
Gallardo-Rodriquez 2023 Mexico [ ] | ALL | RCT Pilot 3-arm | 33 (11/11/11) (66.7) | Mean 23.7 (18–45) CEG: 20.5 (18–36) REG: 22.5 (18–36) CG: 28.0 (18–45) | Neutropenia, infections, bleeding at admission, were nonmotile or unable to carry out exercise; with a CNS disease preventing movement, alterations of heart function, with bone marrow or CNS relapse, with a referral from another hospital | During chemotherapy treatment | , hospital- and home-based: T: Cross-training or resistance (weights) exercises I: RPE of 3–6 (50–75% of HRR), 3–5 sets of 8–15 reps L: 30–50 min, 3–5x/week D: During inpatient period | Moderate | T: Mobilization I: Low L: 30 min, daily |
Hacker 2017 USA [ ] | ALL, AML, CLL, CML, HL, NHL, MM, MDS | RCT | 67 (33/34) (38.8) | Mean 53.3 IG: 51.9 CG: 54.6 | Significant comorbidity, like impending pathological fracture, making exercise potentially unsafe | During and after ASCT or allo-HSCT | Supervised, hospital-based: T: Progressive resistance training (elastic resistance bands and body weights) I: Moderate intensity, Borg scale 13 L: 2–3x/week, D: During inpatient period Unsupervised, home-based: T: Progressive resistance training (elastic resistance bands and body weights) I: Moderate intensity, Borg scale 13 L: 2–3x/week D: 6 weeks after discharge | Moderate | T: UC, Attention control with health education |
Hacker 2022 USA [ ] | MM | RCT Pilot | 32 (17/15) (34.4) | Mean 62.78 IG: 62.21 CG: 63.44 | NR | After ASCT and after discharge | Supervised, hospital-based: T: Weekly goal setting, daily step tracking, and individualized coaching I: NR L: Daily Unsupervised, home-based: T: Free-living PA, step trackers I: NR L: Daily D: 6 weeks | Moderate | T: UC, Recommendations regarding rest, PA, and exercise |
Hathiramani 2020 UK [ ] | Lymph | RCT | 46 (23/23) (63) | Mean 61 IG: 61.5 CG: 60.4 | Active disease, unstable angina or unexplained electrocardiogram, poor PS (ECOG 3 or more), pregnancy, difficulty breathing at rest, persistent cough, fever or illness, or any cognitive impairment limiting the ability to give informed consent or complete questionnaires | During and after chemotherapy | , home-based: T: Individual elements of aerobic (walking), resistance training (resistance bands, body weight), core stability and stretches I: Aerobic: Moderate intensity Resistance: ACSM guidelines with 3 sets for 8–12 rep L: 50 min, 3x/week D: 12 weeks | Moderate | T: Bed or chair-based program, mindfulness-based. CD audio guidance to relaxation techniques: mindfulness meditation, breathing exercises, guided visualization and progressive muscle relaxation. I: No advice to exercise outside of normal habits, nor asked to avoid activity L: 50 min, 3x/week |
Huberty 2019 USA [ ] | MPN: Polycythaemia Vera, Essential, Thrombocythemia, Myelofibrosis | RCT Pilot | 62 (34/28) (93.7) | Mean 56.9 IG: 58.3 CG: 55.0 | Reported performing tai chi, qi gong, or yoga for ≥60 min/week, reported engaging in ≥150 min/week of PA, utilized the study’s online yoga site: Udaya.com, (accessed on 21 August 2024) syncope in the last two months, recurrent falls: ≥2 in past two months, score of ≥15 on the PHQ-9, score of >3 on the ECOG-3, pregnant, residency outside USA | During or after chemotherapy | , home-based: T: Online homebased Hatha/Vinyasa yoga I: NR L: 5–30 min, 60 min/week D: 12 weeks | Less | T: UC, Maintain usual activity |
Hung 2014 Australia [ ] | Lymph, ML | RCT Pilot | 37 (18/19) (46) | Mean IG: 57.5 CG: 59.9 | Undergoing allo-HSCT, deemed unsuitable for study participation by physicians | After ASCT | , home-based: T: Individual telephone-delivered nutrition and exercise counselling, unsupervised aerobic (walking or cycling) and resistance (sit-to-stand or free weight) I: Recommendations based on ACSM guidelines for cancer survivors L: Various length, 3–7x/week D: 12 weeks | Moderate | T: UC |
Jacobsen 2014 USA [ ] | ALL, CML, CLL, MDS, MM, Lymph | RCT 4-arm | 711 (180/178/178/175) (43) | Median IG E: 58 (20–76) IG SM: 58 (20–75) IG E/SM: 57 (18–75) CG: 55 (19–76) >65, n = 154 (21.6%) | Orthopaedic, neurological, or other problems that prevented safe ambulation or protocol adherence, participation in another clinical trial with QoL or functional status as a primary endpoint, planned anticancer therapies other than tyrosine kinase inhibitor or rituximab within 100 days after HSCT, planned donor lymphocyte infusion within 100 days after HSCT, planned tandem transplantation | Before, during and after allo-HSCT or ASCT | , home-based: T: Self-directed exercise program, a DVD reinforcing the program, tracking of participation in exercise and/or stress management. Exercise component: Calculation of target HR and pedometer. The stress management component also included provision of a relaxation CD I: 50–75% of estimated HRR L: 20–30 min, 3–5x/week D: 180 dayS | Moderate | T: DVD with general instruction about HSCT L: 45 min |
Jarden 2009 Denmark [ ] | CML, AML, ALL, AA, MDS, WM, PNH, MF | RCT | 42 (21/21) (38.1) | Mean 39.2 (18–60) IG: 40.9 (18–60) CG: 37.4 (18–55) Median 40.5 IG: 45.0 CG: 38.0 | Prior HSCT, recent cardiovascular, or pulmonary disease, abnormal EKG, psychiatric disorder, and motor, musculoskeletal or neurological dysfunction requiring walking aids and bony metastasis. Prior to testing: Signs of infection, anaemia, neutropenia, or thrombocytopenia, disqualified or testing postponed | During allo-HSCT | , hospital-based: T: Multimodal program of aerobic (ergometer), resistance (machines and weights) and active exercises, progressive relaxation, and psychoeducation I: Aerobic: Low to moderate, 50–75% HR max. RPE: 10–13. Dynamic and stretching 1–2 sets, 10–12 reps. Static: 1 set, hold for 15–30 s. Resistance: Low to moderate, 1–2 sets of 10–12 reps. Progressive relaxation: low L: 60–70 min, 3–5x/week D: 4–6 weeks | Moderate | T: UC, Conventional treatment and care, standard care for PA, PT is individualized, not providing a stationary cycle unless requested L: PT < 1½ hour/week, after allogeneic HSCT (day +1) |
Jarden 2016 Denmark [ ] Jarden 2021 Denmark [ ] | Acute Leuk, AML de novo, AML following MDS, APL, ALL | RCT | 70 (34/36) (41.4) | Mean 53.1 (19.8–73.7) IG: 51.1 (19.8–70.0) CG: 55.0 (20.3–73.7) | Severe or unstable psychological, cardio-respiratory, neurological, or musculoskeletal disease, secondary active malignancy, abnormal EKG | During chemotherapy | , hospital-based: T: Multimodal intervention of aerobic (ergometer), strength (weights) and relaxation exercise, nutrition support, pedometer, and health counselling I: Aerobic: 75–80% of HRmax. Dynamic resistance: Moderate to hard, 2 sets, 12 reps L: 60 min, 3x/week D: 12 weeks | Extensive | T: UC |
Kim 2005 South Korea [ ] | AML, ALL, SAA | RCT | 35 (18/17) (51.4) | Mean IG: 32.9 CG: 34.3 (20–48) | Medicated for anxiety or depression | After allo-HSCT | , hospital-based: T: Individual physical exercises combined with relaxation breathing I: NR L: 30 min/daily D: 6 weeks | Less | T: UC, Routine care |
Knols 2011 Switzerland [ ] | AML, CLL, ALL, HL, NHL, MM, Osteo-myelofibrosis, Leuk, Amyloidosis, Testicular C. | RCT | 131 64/67 (41.2) | Mean 46.7 IG: 46.6 (18–75) CG: 46.6 (20–67) | GvHD except for grade I not requiring treatment, painful joints, unstable osteolysis, chronic pain, lesions of the central or peripheral nervous system, uncontrolled cardiovascular disease, thyroid disease, or diabetes | After allo-HSCT or ASCT | , physiotherapy practice or fitness centre: T: Individual, physical exercises with both endurance aerobic (ergometer or walking tread mill) and resistance strength (machines and dumbbells) exercises I: Individual HR (from 50–60%, increasing to 70–80% of estimated HR max) L: 30 min, 2x/week D: 12 weeks | Moderate | T: UC |
Kobayashi 2020 Japan [ ] | AML, DLBCL, ALL | RCT Crossover | 33 (13/20) (18.2) | Mean Wii PT/Therapist PT: 44.9 Therapist PT/Wii PT: 44.6 | Grade 2 or worse CTC for Adverse Events version 4.0 | During chemotherapy | , hospital-based: T: Individual aerobic and resistance exercises using the Wii Fit balance board I: NR L: 30 min, 5x/week D: 1 week (and then crossover) | Less | T: Individual aerobic and resistance exercises. I: Aerobic: 40–60%. Resistance: Borg 11–13 L: 30 min, 5x/week D: 1 week and then crossover |
Koutoukidis 2020 UK [ ] | MM, Myeloma IgG, Myeloma IgA, Myeloma Light chain, non-sec/oligo-sec. | RCT | 131 (89/42) (45) | Median IG: 64 (35–86) CG: 63 (40–80) | Spinal instability. Recent spinal or other surgery for pathological fractures within 4 weeks. Abnormal EKG with unexplained clinical indication after cardiological work-up. At risk of pathological fracture based on Mirel’s score. Currently enrolled in research exercise study. Unstable angina. Musculoskeletal mobility limitations. Cognitive impairment hindering completion of questionnaire | After auto-HSCT, radiotherapy or chemotherapy | Supervised, hospital-based: T: Individual aerobic (treadmill walking, ergometer, cross-trainer or stepping) and resistance (weightlifting, body weight or resistance bands) training, exercise diaries, goal setting with physiotherapist I: Aerobic: 50–75% of predicted HR max-Resistance: 10 RM L: 1x/week D: 6 months Unsupervised, home-based: T: Individual aerobic training and resistance training, exercise diaries, goal setting with PT I: Aerobic: 50–75% of predicted HR max. Resistance: 10 RM L: Max 30 min, 2–3x/week D: 6 months | Moderate | T: UC |
McCourt 2023 UK [ ] | MM | RCT Pilot | 50 (23/27) (38) | Mean 60.4 (37–72) IG: 59.3 (37–72) CG: 61.3 (40–72) | Declined or not suitable for auto-HSCT or too close to transplantation, restricted mobility, non-English language | Before, during and after ASCT | Supervised, hospital-based: T: Aerobic (treadmill walking or ergometer) and resistance (machines and resistance bands) exercise and behaviour change support I: Aerobic: 60–80% of HRR. Resistance: 10 RM and individually tailored to progress and/or adapt to bone disease. L: 1x/week Unsupervised, home-based: T: Aerobic (walking) and resistance (resistance bands) exercise and behaviour change support, virtual I: Aerobic: 60–80% of HRR. Resistance: 10 RM and individually tailored to progress and/or adapt to bone disease L: Aerobic exercise (Phase 1 and 3): 15–40 min, 3x/week. Resistance exercise (Phase 1 and 3): 3x/week. During phase 2 (transplant admission) | Extensive | T: UC |
Mello 2003 Brazil [ ] | CML, AML, SAA, NHL, MDS | RCT | 18 (9/9) (55.6) | Mean IG: 27.9 (18–39) CG: 30.2 (18–44) | NR | During and after allo-HSCT | , hospital-based: T: Individualized exercise program with active exercise, muscle stretching and treadmill walking I: Progressing, no higher than 70% of HR max L: 40 min, 5x/week D: 6 weeks | Moderate | NR |
Oechsle 2014 Germany [ ] | AML, NHL, MM, Germ cell | RCT Pilot | 58 (29/29) (29.2) | Mean IG: 51.7 CG: 52.9 | Symptomatic cardiovascular diseases, tumor infiltration of the skeletal system with risk of pathologic fractures or compression of spinal cord, epilepsy, rheumatologic diseases, BMI < 18, BMI > 30, insufficient cognitive function, inadequate knowledge of German language for questionnaire analysis | During chemotherapy | , hospital-based: T: Aerobic (ergometer) and strength (body weights and resistance bands) training I: Ergometer individually adjusted Strength training: Up to 20 min at 40–60% of estimated 1 RM, sets of 16–25 repetitions L: 30–40 min, 5x/week D: Median: 21 days | Moderate | T: UC, Standard PT |
Pahl 2018 Germany [ ] | Leuk, AML, ALL, APL, NHL, HL, T-cell lymph, WM, MM, PMF | RCT Pilot | 17 (10/7) (30) | Median 55 (47–63) IG: 47 (19–62) CG: 56 (32–63) | Unstable bone metastasis, knee or hip endoprosthesis, epilepsy, pacemaker, severe cardiovascular disease and threshold blood-count values below safety criteria, stents, or former joint injuries | During chemotherapy | , hospital-based: T: Whole body vibration (Galileo Sport vibration platform), including three sets of two to four different exercises (body weight) I: Borg scale 14–16 L: 20 min, 3x/week D: Median: 27 days | Moderate | T: Aerobic exercise; ergometer I: Borg scale 14–16 L: 20 min. |
Pahl 2020 Germany [ ] | AML, ALL, CLL, CMML, MDS, Lymph, MM, MF, Septic granulomatosis Immuno-deficiency, SAA | RCT | 44 (18/26) (31.8) | Median IG: 55 (50–63) CG: 56 (32–63) | Unstable bone metastasis, endoprosthesis of knee or hip, epilepsy, pacemaker, and severe cardiovascular disease | During allo-HSCT | , hospital-based: T: Whole body vibration (Galileo Sport vibration platform) I: NR L: 20 min, 5x/week D: 35–44 days | Moderate | T: Mobilization and stretching L: 5x/week |
Persoon 2017 Netherlands [ ] | MM, (N)HL, Lymph | RCT | 109 (54/55) (36.7) | Median 55 (19–67) IG: 53.5 (20–67) CG: 56 (19–67) | NR | After ASCT | , at local physiotherapy practices: T: Aerobic interval (cycling) and resistance (machines) training, counselling sessions (5x) I: Resistance: High intensity. Week 1–12 2 × 10 rep at 65–80% of 1 RM, week 12–18 2 × 20 rep at 35–40% of 1 RM L: 60 min, 1–2x/week D: 18 weeks | Extensive | T: UC, Not encouraged to exercise, participate in sports, PT, or rehabilitation programs |
Potiaumpai 2021 USA [ ] | AML, ALL, CML, MDS, MM, other Lymph | RCT | 35 (19/16) (45.7) | Mean 58.8 IG: 59.3 CG: 58.2 | Dementia, altered mental status, severe psychiatric conditions, pre-existing comorbid conditions that would contraindicate exercise testing, concurrent non-transplant-related chemotherapy, or radiation | Before and after allo-HSCT or ASCT | , hospital-based: T: Multidirectional drills and walking program I: Exertion level of moderate intensity during the multidirectional drills and a high intensity during the walking portion L: 5–30 min, 3x/weeks D: Varied | Moderate | T: UC |
Safran 2022 Turkey [ ] | AML, B-cell ALL, T-cell ALL, MDS, NHL, MF | RCT | 43 (21/22) (51.6) | Mean IG: 38 (23–63) CG: 40.5 (24–58) | <18 years, ECOG > 3, comorbidities causing fatigue (e.g., multiple sclerosis, Parkinson’s disease, heart failure), rapid deterioration of general condition (sudden uncontrolled weight loss, confused consciousness, high CRP values), brain metastases or metastases to the femur, DVT within last 6 months, neuropathy, and rejecting NMES intervention or exercise therapy | During chemotherapy, after allo-HSCT | , hospital-based: T: Resistance exercise (body weights and resistance bands) combined with neuromuscular electrical stimulation I: Borg scale: Initial recommended RPE is 12–13 and is increased to about 15–16. The intensity was adjusted to a target score of 12–14 (moderate level) using the RPE scale. Intensity (~RPE 15–16) and resistance were gradually increased L: 60–90 min, 2–3x/week D: 4 weeks | Moderate | T: Resistance exercise L: 40–60 min, 2–3 days/week |
Schumacher 2018 Germany [ ] | MM, AML/MDS, NHL Teratoma, CML, CLL | RCT feasibility | 42 (19/23) (40.5) | Median IG: 56.0 (21–65) CG: 56.5 (21–65) | Lack of compliance. Intercurrent diseases, like pulmonary and cardiac insufficiency or uncontrolled infections | During and after allo-HSCT or ASCT | , hospital-based: T: Exergaming on Nintendo Wii for exercising ping pong, tennis, boxing, frisbee, or aerobics and balance I: NR L: 30 min, 5x/week D: During and 30 days post HSCT | Moderate | T: PT program, eccentric and concentric movements, from supine to standing, walking, stepping or treadmill walking, stretching, strength exercise i.e., elastic bands and body weight |
Shelton 2009 USA [ ] | Lymph, Leuk | RCT | 53 (26/27) (37.7) | Mean IG: 43.7 (22–68) CG: 48.9 (29–70) | <18 years, psychiatric disorder, significant cardiovascular disease, paraplegic or hemiplegic, unable to speak or understand English | After allo-HSCT | , hospital-based: T: Aerobic (treadmill and ergometer) and resistance (weights and machines) exercises I: Aerobic: 60–75% of age-predicted HR max. Strength: 1–3 sets of 10 reps L: 20–30 min aerobic, resistance individual, 3x/week D: 4 weeks | Moderate | T: multidisciplinary, inpatient, educational session incl. focus on staying active, information to exercise safely |
Streckmann 2014 Germany [ ] | HL, B-NHL, T-NHL, MM | RCT | 56 (28/28) (25) | Mean IG: 44 (20–67) CG: 48 (19–73) | Unstable osteolysis, severe acute infections, severe cardiac and pulmonary impairments, restrictions for PA | During chemotherapy | , hospital-based: T: Aerobic (treadmill and ergometer), sensorimotor and strength (resistance bands) training I: Initial 60–70% HR max. At the end of session 70–80%. Sensorimotor training: Progressively increasing task difficulty. Strength training: 1 min at max force L: 60 min, 2x/week D: 36 weeks | Extensive | T: UC, Standard clinical care, incl. PT |
Vallerand 2018 Canada [ ] | Leuk., HL, NHL | RCT | 51 (26/25) (60.8) | Mean 52.6 <60: n = 33 >60: n = 18 | Chronic medical condition precluding from aerobic exercise, plan of being away from home > 2 weeks, baseline exercise levels of ≥240 min. weekly | During or after chemotherapy, radiation, HSCT | , home-based: T: Tele counselling with PA guidance with a goal of increasing aerobic exercise (walking, group fitness) levels by at least 60 min/week up to 300 min/week of moderate-vigorous aerobic exercise I: Aerobic exercise: Moderate-vigorous L: Tele-health calls: Mean: 17 min, 1x/week. Aerobic: 60–300 min/week. D: 12 weeks | Moderate | T: UC, PT guidelines, goal setting of increasing aerobic exercise levels I: Aerobic exercise: moderate-vigorous L: 60–300 min/week |
Waked 2019 Egypt [ ] | ALL | RCT | 54 (27/27) (34) | Mean IG: 33.4 CG: 32.4 | Antecedent neurological, developmental, or genetic disorder. Relapsed or secondary ALL. Received testicular, mediastinal, or craniospinal irradiation. Growth hormone insufficiency, hormone therapy. Medications that interfere with lipid metabolism. Diseases affecting cholesterol metabolism such as diabetes mellitus, thyroid dysfunction, or nephrotic syndrome | After treatment | , hospital-based: T: Aerobic training (ergometer) I: 60% of predictive age HR max L: 30–40 min, 3x/week D: 12 weeks | Moderate | T: UC, Normal daily activities |
Wehrle 2019 Germany [ ] | AML, ALL | RCT Pilot 3-arm | 29 (9/10/10) (41) | Median EG: 47.7 (21.9–63.4) RG: 47.4 (41.2–62.2) CG: 50.6 (35.0–58.1) | Karnofsky score < 60, uncontrolled hypertension, cardiac illness (NYHA III-IV), instable bone metastases, lack of informed consent after screening | During chemotherapy | , hospital-based: T: Either aerobic (ergometer or treadmill) or resistance (body weight) training I: Endurance: 60–70% of HRmax, RPE of 12–14 Resistance: RPE 12–14 L: 30–45 min, 3x/week D: 5 weeks (median) | Moderate | T: Mobilization and stretching program, I: low intensity |
Wiskemann 2011 Germany [ ] Wiskemann 2014 Germany [ ] | AML, ALL, CML, CLL, MDS, Sec. AML, MPS, MM, other Lymph, AA | RCT | 105 (52/53) (32.4) | Mean 48.8 (18–71) IG: 47.6 (18–70) CG: 50 (20–71) | NR | Before, during and after allo-HSCT | , hospital-based and home-based: T: Aerobic (ergometer/treadmill or walking) and resistance (resistance bands) exercises I: Tailored intensity. Endurance: Borg scale: 12–14. Resistance: Borg scale: 14–16 w/8–20 rep × 2–3 sets L: 20–40 min, 2–5x/week. Endurance: 3–5x/week. Resistance: 2x/week | Moderate | T/I: Recommend moderate PA, received step counters L: Same frequency of social contact as in IG. PT up to 3x/week |
Wood 2020 USA [ ] | AML, MDS, ALL, CML, HL, MM, MF, AA, MCL, HLH | RCT Pilot | 34 (17/17) (43) | Median 52 (28–73) | Transplant ineligibility, uncertain transplant candidacy, comorbid illness that would preclude maximal effort during exercise testing or participation in regular exercise determined by the treating physician or study exercise physiologist | Before allo-HSCT | , home-based: T: Aerobic exercise (walking, jogging, running, cycling, cross trainer or stair climbing) I: 80% HR max. From week 2 Interval, 2 min 80%, 3 min low recovery L: 30 min, 3–4x/week D: Mean: 11 weeks | Moderate | T: Fitbit Surge, no further instructions and information |
Yeh 2016 Taiwan [ ] | NHL | RCT | 108 (54/54) (44.1) | Mean 59.8 (23–90) | Major medical disease, as uncontrolled arrhythmia, hypertension, unstable angina, severe respiratory disease, acute infection, multiple myeloma, bone metastasis, psychiatric disorders. Medical contraindications for exercise, e.g., orthopaedic problems and neurologic or musculoskeletal disturbances, or already practicing qigong or other exercise training programs | During chemotherapy | , home-based: T: Chan-Chuang qigong exercise, guidance booklet and weekly phone call I: NR L: 20–60 min, 2–3x/day (max. 5 times). D: 3 weeks | Less | T: UC |
Outcomes | SMD (95% CI) | Participants Completed Outcome Measures, n Studies, (n) | Quality of Evidence GRADE | Comments |
---|---|---|---|---|
Physical function * 12MWT; 2MSC; 2MWT; 6MWT; Accelerometer; KPS; SWT; TUG | 0.29 (0.12–0.45) | 1219 (25) | ⨁◯◯◯ Very low | Downgraded, due to RoB (majority of trials), Inconsistency (moderate heterogeneity: 48.17%), and risk of Publication bias (Egger’s test p = 0.0516) |
Aerobic capacity Aerobic Power Index; Modified Balke; Modified endurance test; Power Max, Timed Stair Climb; VO2 Max; VO2 Max Relative; VO2 Peak; VO2 Peak modified | 0.53 (0.27–0.79) | 853 (17) | ⨁⨁◯◯ Low | Downgraded, due to Inconsistency (substantial heterogeneity: 69.21%) and risk of Publication bias (Egger’s test p = 0.0443) |
Muscle strength GRIP; Max test; Isometric Knee Extension test; STS | 0.47 (0.17–0.78) | 1091 (25) | ⨁⨁⨁◯ Moderate | Downgraded, due to Inconsistency (substantial/considerable heterogeneity: 82.59%) |
Body composition BMI; BodPod; DEXA; SECA bioimpedance, Tanita Bioelectrical impedance | 0.20 (0.03–0.37) | 654 (12) | ⨁⨁⨁⨁ High | No change |
Physical activity GLTEQ; IPAQ; PASE | 0.32 (−0.00–0.65) | 358 (5) | ⨁◯◯◯ Very low | Downgraded, due to RoB (majority of trials), Inconsistency (moderate heterogeneity: 56.97%), Imprecision (95% CI does not exclude 0), and risk of Publication bias (Egger’s test p = 0.0132) |
QoL Global * CMSAS; EORTC QLQ-C30; FACT; FACT-An; FACT-BMT; FACT-Leu; GLQOL; POMS; PROMIS | 0.34 (0.04–0.64) | 1447 (29) | ⨁⨁◯◯ Low | Downgraded, due to RoB (majority of trials) and Inconsistency (substantial/considerable heterogeneity: 87.39%) |
QoL Emotional CMSAS; EORTC QLQ-C30; FACT-General, FACT-Leu; Happiness Scale; NCCN Distress Thermometer; POMS; PROMIS; SF-12; SF-36 | 0.33 (0.05–0.60) | 1764 (28) | ⨁⨁◯◯ Low | Downgraded, due to Inconsistency (substantial/considerable heterogeneity: 86.93%) |
QoL Functional EORTC QLQ-C30; FACT; FACT-An; FACT-BMT; FACT-Leu; FACT-TOI | 0.33 (0.09–0.57) | 455 (10) | ⨁⨁◯◯ Low | Downgraded, due to RoB (majority of trials), and Inconsistency (moderate heterogeneity: 37.54%) |
QoL Physical CMSAS; EORTC QLQ-C30; FACT-An; FACT-BMT; FACT-Leu; FACT-TOI; PROMIS; SF-12; SF-36 | 0.32 (0.03–0.60) | 1731 (28) | ⨁⨁◯◯ Low | Downgraded, due to RoB (majority of trials) and Inconsistency (substantial/considerable heterogeneity: 87.72%) |
Anxiety HADS; POMS; PROMIS; STAI | 0.21 (0.13–0.55) | 917 (17) | ⨁◯◯◯ Very low | Downgraded, due to RoB (majority of trials), Inconsistency (Substantial/considerable heterogeneity: 84.23%) and Imprecision (95% CI does not exclude 0) |
Depression CES-D; HADS; POMS; PROMIS | 0.37 (0.09–0.64) | 919 (17) | ⨁◯◯◯ Very low | Downgraded, due to RoB (majority of trials), Inconsistency (substantial/considerable heterogeneity: 76.33%), and risk of Publication bias (Egger’s test p = 0.0184) |
Fatigue BFI; EORTC QLQ-C30; FACT-An; FACIT-F; FACT-F; MFI; MPN-SAF; 11-point rating scale; POMS; PROMIS; SCFS | 0.44 (0.16–0.71) | 1860 (31) | ⨁⨁◯◯ Low | Downgraded, due to RoB (majority of trials) and Inconsistency (substantial/considerable heterogeneity: 87.89%) |
Pain EORTC QLQ-C30; PROMIS; SF-36 | 0.43 (0.13–0.73) | 811 (14) | ⨁⨁◯◯ Low | Downgraded, due to RoB (majority of trials) and Inconsistency (substantial/considerable heterogeneity: 77.82%) |
Recruitment IG and CG | Retention IG and CG | Participation | Adverse Events | |||
---|---|---|---|---|---|---|
IG | IG | |||||
Author Year/Country | Sample Size Estimated, n | Eligibility Assessed, n | Included, n | Completed Post-Test, n | Adherence to Exercise (%) | AE Type, n |
Accogli [ ] 2022, Italy | 40 | 193 | 46 | 42 | 90 | No AE |
Alibhai [ ] 2014, Canada | 40 | 232 | 38 | 36 | 28 | NR |
Alibhai [ ] 2015, Canada | 72 | 264 | 81 | 70 | 54 | AE: 4 grade II musculoskeletal events |
Baumann [ ] 2010, Germany | 60 | NR | 64 | 49 | NR | NR |
Baumann [ ] 2011, Germany | 45 | NR | 47 | 33 | NR | No AE |
Bayram [ ] 2024, Turkey | 28 | 39 | 30 | 26 | 20 (IMT) | No AE |
Bird [ ] 2010, UK | 132 | 158 | 58 | 46 | NR | No AE |
Bryant [ ] 2018, USA | 30 | 82 | 18 | 17 | 80 | No AE |
Chang [ ] 2008, Taiwan | NR | 28 | 24 | 22 | NR | No AE |
Chen [ ] 2021, China | 30 | 46 | 30 | 29 | 98 | NR |
Chow [ ] 2020, USA | 41 | 420 | 41 | 37 | 75 | NR |
Chuang [ ] 2017, Taiwan | 100 | 105 | 100 | 96 | 96 | No AE |
Cohen [ ] 2004, USA | 38 | NR | 39 | 30 | 32 | NR |
Coleman [ ] 2003, USA | NR | NR | 24 | 13 | NR | No AE |
Coleman [ ] 2012, USA | 200 | NR | 187 | 166 | NR | NR |
Courneya [ ] 2009, Canada | 120 | 1306 | 122 | 117 | 92 | No SAE. AE: 3 back, hip, and knee pain |
Defor [ ] 2007, USA | NR | 122 | 100 | 85 | 24 | NR |
Eckert [ ] 2022, USA | NR | 326 | 72 | 43 | NR | No AE |
Furzer [ ] 2016, Australia | NR | 89 | 44 | 37 | 91 | No SAE. AE: 2 minor exercise modifications due to pre-existing knee and back injuries |
Gallardo-Rodriquez [ ] 2023, Mexico | 114 | 50 | 33 | 18 | NR | No (significant) AE |
Hacker [ ] 2017, USA | NR | 118 | 67 | 67 | 83 | NR |
Hacker [ ] 2022, USA | NR | 45 | 32 | 30 | NR | NR |
Hathiramani [ ] 2020, UK | 46 | 62 | 46 | 38 | NR | No AE |
Huberty [ ] 2019, USA | NR | 260 | 62 | 48 | 15 | No AE |
Hung [ ] 2014, Australia | NR | 55 | 37 | 33 | NR | No AE |
Jacobsen [ ] 2014, USA | 700 | NR | 711 | 560 | NR | No AE |
Jarden [ ] 2009, Denmark | 40 | 82 | 42 | 34 | NR | No AE |
Jarden [ ] 2016, Denmark Jarden [ ] 2021, Denmark | 70 | 170 | 70 | 62 | 71 | No SAE. AE: 8: sport-related (n = 5), cardioresp (n = 5), dizziness (n = 3), gastrointestinal (n = 3), pain/discomfort (n = 2) and bruising (n = 1) |
Kim [ ] 2005, S. Korea | 42 | NR | 42 | 35 | NR | NR |
Knols [ ] 2011, Switzerland | 128 | 310 | 131 | 114 | 85 | No AE |
Kobayashi [ ] 2020, Japan | 32 | 33 | 33 | 22 | 67 | No AE |
Koutoukidis [ ] 2020, UK | 140 | 313 | 131 | 99 | 75 | No AE |
McCourt [ ] 2023, UK | NR | 123 | 50 | 33 | NR | No SAE. AE: 1 mild episode of dizziness |
Mello [ ] 2003, Brazil | NR | 32 | 18 | 18 | NR | NR |
Oechsle [ ] 2014, Germany | 48 | NR | 58 | 48 | NR | No AE |
Pahl [ ] 2018, Germany | NR | 121 | 20 | 11 | 62 | No AE |
Pahl [ ] 2020, Germany | NR | 112 | 71 | 44 | 59 | No SAE. AE: 2 sessions stopped prematurely due to knee pain and discomfort |
Persoon [ ] 2017, The Netherlands | 120 | 469 | 109 | 97 | 86 | AE: 1 strained calf muscle |
Potiaumpai [ ] 2021, USA | NR | 57 | 36 | 32 | 79 | NR |
Safran [ ] 2022, Turkey | 32 | 77 | 43 | 31 | NR | No AE |
Schumacher [ ] 2018, Germany | NR | 49 | 42 | 31 | NR | No AE |
Shelton [ ] 2009, USA | 164 | 250 | 61 | 53 | 75 | NR |
Streckmann [ ] 2014, Germany | 184 | 186 | 61 | 51 | 65 | No AE |
Vallerand [ ] 2018, Canada | 50 | 407 | 51 | 51 | 93 | No AE |
Waked [ ] 2019, Egypt | 54 | 60 | 54 | 50 | NR | NR |
Wehrle [ ] 2019, Germany | 36 | 39 | 29 | 22 | 68 | No AE |
Wiskemann [ ] 2011, Germany Wiskemann [ ] 2014, Germany | NR | 141 | 105 | 80 | 87 | NR |
Wood [ ] 2020, USA | 60 | 113 | 34 | 16 | NR | NR |
Yeh [ ] 2016, Taiwan | 64 | 118 | 108 | 102 | 100 | No AE |
Total | NR (n = 16) | 7262 NR (n = 8) | 3552 | 2924 (82.3%) | Mean: 70% (15–100) NR (n = 21) | No AE (n = 26) AE (n = 7) SAE (n = 1) NR (n = 15) |
Trial Identifier Design | Investigator Country | Title | Diagnosis | Sample Size, n | Age | Intervention Type and Duration | Treatment Trajectory | Primary Outcome | Study Status |
---|---|---|---|---|---|---|---|---|---|
NCT05642884 RCT | Smith Giri USA | Prehabilitation Feasibility Among Older Adults Undergoing Transplantation | MM | 30 | >60 years | Home-based prehabilitation multimodal exercise program delivered using a telehealth format 8 weeks | Before ASCT | Feasibility | Recruiting 2023-07-10 Estimated completion 2025-12-31 |
NCT04898790 RCT | Thuy Koll USA | Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant (PROACTIVE) | Leukemia Lymphoma MM MDS MPN | 88 | >60 years | Partially supervised PA in the Community Health Activities Model Program for Seniors 12 weeks | Undergoing HSCT | Change in executive function and working memory | Recruiting 2021-11-18 Estimated completion 2025-04 |
NCT04670029 RCT | Magali Bavaloine France | Impact of an APA Program on EFS in Patients with Diffuse Large-cell B Lymphoma Treated in 1st Line (PHARAOM) | Diffuse Large B Cell Lymphoma | 186 | >65 years | Partially supervised adapted physical activity with aerobic and anaerobic sessions on site and at home | During treatment | To detect an absolute difference of 15% in event-free survival between groups | Recruiting 2021-09-08 Estimated completion 2029-02 |
NCT04057443 RCT | Maite Antonio Spain | Nutritional and Physical Exercise Intervention in Older Patients with Malignant Hemopathies | MDS LPS MM | 80 | >70 years | Nutritional support according to nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). Diet counselling, oral supplemented nutrition, enteral or parenteral nutrition. Exercise program with a mixed structure, designed individually with group sessions. 24 weeks, 3 days a week | During treatment | Adherence to oncological treatment from baseline to post treatment or 6 months. Difference between dose administered and prescribed. | Unknown status Start 2019-04-11 Estimated completion 2023-06-01 |
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Jarden, M.; Tscherning Lindholm, S.; Kaldan, G.; Grønset, C.; Faebo Larsen, R.; Larsen, A.T.S.; Schaufuss Engedal, M.; Kramer Mikkelsen, M.; Nielsen, D.; Vinther, A.; et al. Limited Evidence for the Benefits of Exercise in Older Adults with Hematological Malignancies: A Systematic Review and Meta-Analysis. Cancers 2024 , 16 , 2962. https://doi.org/10.3390/cancers16172962
Jarden M, Tscherning Lindholm S, Kaldan G, Grønset C, Faebo Larsen R, Larsen ATS, Schaufuss Engedal M, Kramer Mikkelsen M, Nielsen D, Vinther A, et al. Limited Evidence for the Benefits of Exercise in Older Adults with Hematological Malignancies: A Systematic Review and Meta-Analysis. Cancers . 2024; 16(17):2962. https://doi.org/10.3390/cancers16172962
Jarden, Mary, Sofie Tscherning Lindholm, Gudrun Kaldan, Charlotte Grønset, Rikke Faebo Larsen, Anders Thyge Steen Larsen, Mette Schaufuss Engedal, Marta Kramer Mikkelsen, Dorte Nielsen, Anders Vinther, and et al. 2024. "Limited Evidence for the Benefits of Exercise in Older Adults with Hematological Malignancies: A Systematic Review and Meta-Analysis" Cancers 16, no. 17: 2962. https://doi.org/10.3390/cancers16172962
Article access statistics, supplementary material.
ZIP-Document (ZIP, 12748 KiB)
Mdpi initiatives, follow mdpi.
Subscribe to receive issue release notifications and newsletters from MDPI journals
IMAGES
VIDEO
COMMENTS
This article is a practical guide to conducting data analysis in general literature reviews. The general literature review is a synthesis and analysis of published research on a relevant clinical issue, and is a common format for academic theses at the bachelor's and master's levels in nursing, physiotherapy, occupational therapy, public health and other related fields.
Reviews of the professional literature have consistently found that many applications of EFA are marked by an injudicious choice of methods and incomplete reports. ... Gaskin C. J., Happell B. (2014). On exploratory factor analysis: A review of recent evidence, an assessment of current practice, and recommendations for future use. International ...
Exploratory research can help you narrow down your topic and formulate a clear hypothesis and problem statement, as well as giving you the "lay of the land" on your topic. Data collection using exploratory research is often divided into primary and secondary research methods, with data analysis following the same model. Primary research
9.3. Types of Review Articles and Brief Illustrations. EHealth researchers have at their disposal a number of approaches and methods for making sense out of existing literature, all with the purpose of casting current research findings into historical contexts or explaining contradictions that might exist among a set of primary research studies conducted on a particular topic.
Exploratory factor analysis (EFA) is a powerful statistical technique that enables researchers to use their judgement and interpretation to identify a set of latent factors that meaningfully and parsimoniously represent a set of indicators (Goretzko et al., 2021, Hair et al., 2019, Howard, 2016, Watkins, 2018).The technique estimates the number of latent factors underlying the indicators as ...
Manual exploratory literature reviews should be a thing of the past, as technology and development of machine learning methods have matured. The learning curve for using machine learning methods is rapidly declining, enabling new possibilities for all researchers. A framework is presented on how to use topic modelling on a large collection of papers for an exploratory literature review and how ...
2.7 Extraction and analysis of data. Data were extracted in the process of scoping literature reviews, including information with regards to formulating the problem, establishing and validating the review procedure, searching the literature, screening for inclusion, evaluating quality, extracting data, analyzing and synthesizing data, and reporting the findings (Xiao & Watson, 2019).
Exploratory Factor Analysis. Exploratory Factor Analysis (EFA) is widely used in medical education research in the early phases of instrument development, specifically for measures of latent variables that cannot be assessed directly. ... Typically, in EFA, the researcher, through a review of the literature and engagement with content experts ...
Different solutions have been recommended in the extant literature to deal with this weakness, such as the use of mixed methods (e.g., Opoku et al., 2016), the support of the chosen methodology through a detailed research protocol (e.g., Yin, 2003), or the support of a study through a systematic literature review (e.g., Tranfield et al., 2003 ...
4. Choosing between factor analysis and principal components analysis4.1. Review of literature. Factor analysis and PCA are separate data extraction procedures, each with their own purpose and model (Schmitt, 2011, Thomson, 1939, Widaman, 2007).Some authors have argued that the purpose of factor analysis is to explain the correlations between items in terms of one or more latent factors ...
As mentioned previously, there are a number of existing guidelines for literature reviews. Depending on the methodology needed to achieve the purpose of the review, all types can be helpful and appropriate to reach a specific goal (for examples, please see Table 1).These approaches can be qualitative, quantitative, or have a mixed design depending on the phase of the review.
What is a literature review? Definition: A literature review is a systematic examination and synthesis of existing scholarly research on a specific topic or subject. Purpose: It serves to provide a comprehensive overview of the current state of knowledge within a particular field. Analysis: Involves critically evaluating and summarizing key findings, methodologies, and debates found in ...
1.3.1.2 Empirical. An empirical literature review collects, creates, arranges, and analyzes numeric data reflecting the frequency of themes, topics, authors and/or methods found in existing literature. Empirical literature reviews present their summaries in quantifiable terms using descriptive and inferential statistics.
Qualitative, narrative synthesis. Thematic analysis, may include conceptual models. Rapid review. Assessment of what is already known about a policy or practice issue, by using systematic review methods to search and critically appraise existing research. Completeness of searching determined by time constraints.
Abstract. As the name suggest a good literature review is always comprehensive and contextualized with respect to the research. It provides the reader or the target audience with a base of the theory base along with a survey of published works that pertain to the investigation of the researcher and further an analysis of that particular work.
Exploratory Search. Once you have an initial research question, you can develop and refine your research question and eligibility criteria through exploratory searching.Exploratory searching is also called preliminary, initial, and naive or novice searching.Regardless of what you call it, it is simply a series of searches conducted prior to starting the review with the goal of producing a well ...
A systematic literature review of exploratory factor analyses in management. September 2023. Journal of Business Research 164 (1):113969. 164 (1):113969. DOI: 10.1016/j.jbusres.2023.113969 ...
LITERATURE REVIEW . Exploratory data analysis (EDA) is an important first step in the data analysis process that involves exploring and . ... Exploratory data analysis (EDA) is a well-established ...
We also conducted an exploratory study of over 2700 AI-enabled healthcare startups worldwide to supplement our literature review. The SLR reveals several gaps within the research scope and ...
Later, we present a systematic literature review of 50 state-of-the-art visual data analytics tools and their utility in six distinct steps of the Exploratory Data Analysis (EDA) process. We also investigate the extent to which these modern visual EDA tools address scalability, interpretability, and analytical expertise challenges of analyzing ...
DOI: 10.1016/j.techsoc.2023.102321 Corpus ID: 259347766; Artificial intelligence innovation in healthcare: Literature review, exploratory analysis, and future research @article{Zahlan2023ArtificialII, title={Artificial intelligence innovation in healthcare: Literature review, exploratory analysis, and future research}, author={Ahmed Zahlan and Ravi Ranjan and David Hayes}, journal={Technology ...
An exploratory analysis of participants in whom normoglycaemia was achieved in the SURPASS 1-4 studies has recently been reported, ... Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the ...
Design, Setting, and Participants This was an exploratory analysis of the Pediatric Adenotonsillectomy Trial for Snoring (PATS) randomized clinical trial of adenotonsillectomy vs watchful waiting for mild oSDB (snoring with obstructive apnea-hypopnea index of <3 events/hour) that took place at 7 pediatric tertiary care centers across the US and ...
Background and Objectives: We investigated the effects of using a BiZact™ device for tonsillectomy on operating time, intraoperative blood loss, postoperative bleeding rate, and pain through a meta-analysis of the relevant literature. Materials and Methods: We reviewed studies retrieved from the databases of PubMed, SCOPUS, Google Scholar, Embase, Web of Science, and Cochrane up to March ...
Current approaches to gas path analysis are extended by incorporating EO data. The analytical approach is presented in combination with a literature review. The literature review covers the following topics: flight trajectory modeling, EO/environmental condition data, as well as engine performance, condition, and deterioration modeling.
Analysis Source. IMPACT Initiatives; Posted 29 Aug 2024 ... launched an in-depth literature review at the beginning of 2024 to understand what the emerging innovations and best practices in the ...
The second step of the review is illustrated in Fig. 2, where we performed a systematic process following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [29] to select research articles for inclusion in this SLR.In the first stage of our investigation, we looked through the keywords listed in Table 2.The search was conducted with the selected keywords ...
Older patients receiving antineoplastic treatment face challenges such as frailty and reduced physical capacity and function. This systematic review and meta-analysis aimed to evaluate the effects of exercise interventions on physical function outcomes, health-related quality of life (QoL), and symptom burden in older patients above 65 years with hematological malignancies undergoing ...
Abstract. This paper presents an end-to-end analysis of Fintech-driven sandboxes, with a particular focus on Latin America. Contrary to the procedural approach characterizing sandbox research, our analysis adopted the managerial perspective, and resulted in a theoretical and applicable framework.
We review the application and reporting of exploratory factor analysis (EFA) in management. First, we integrate recommendations from relevant reviews and simulation studies to provide modern guidelines regarding EFA for psychometric investigation, and we highlight severe concerns associated with EFA for Harman's one-factor test. Second, we conduct a systematic literature review including ...